AZD4512 / AstraZeneca - LARVOL DELTA

Lumi-NHL: A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - P1/2 | N=91 | Recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Recruiting

Enrollment open • Monotherapy • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

AZD4512: A novel CD22-directed antibody-drug conjugate for the treatment of b-cell malignancies (ASH 2025) - "Toxicology studies showed thatAZD4512 was well-tolerated, with no unexpected side effects. Collectively, these findings highlightAZD4512 as a promising therapeutic candidate for the treatment of patients with B-ALL and B-NHL."

Acute Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD22 • KMT2A

Lumi-NHL: A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - P1/2 | N=91 | Not yet recruiting | Sponsor: AstraZeneca

Monotherapy • New P1/2 trial • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology